Dow Today: Intel (INTC) Leads The Day Higher, Pfizer (PFE) Lags

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 68.0 points (-0.4%) at 16,344 as of Monday, Apr 7, 2014, 9:36 a.m. ET. During this time, 20.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 417.9 million. The NYSE advances/declines ratio sits at 803 issues advancing vs. 1,951 declining with 220 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be Intel (Nasdaq: INTC), which is sporting a 45-cent gain (+1.7%) bringing the stock to $26.61. Volume for Intel currently sits at 2.4 million shares traded vs. an average daily trading volume of 31.7 million shares.

Intel has a market cap of $131.31 billion and is part of the technology sector and electronics industry. Shares are up 0.8% year to date as of Friday's close. The stock's dividend yield sits at 3.6%.

Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Other Intel Architecture, Software and Services, and All Other segments.

TheStreet Ratings rates Intel as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a 79-cent decline (-2.5%) bringing the stock to $31.37. This single loss is lowering the Dow Jones Industrial Average by 5.98 points or roughly accounting for 8.8% of the Dow's overall loss. Volume for Pfizer currently sits at 4.6 million shares traded vs. an average daily trading volume of 27.2 million shares.

Pfizer has a market cap of $207.15 billion and is part of the health care sector and drugs industry. Shares are up 5% year to date as of Friday's close. The stock's dividend yield sits at 3.3%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Google's Waymo Teams With Intel on Self Driving Technology

Buying Nvidia Now Is Like Getting Intel Way Back in 1993, Jim Cramer Says

Amazon, Google and Other U.S. Tech Giants Face a Battle Over Taxes With Europe

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

Cramer: Nvidia Is More Than Just a Pet Name